Combining 2 immunotherapies may make a difference in cancer: CAR T cells and oncolytic viruses

Although the methods we use in cancer treatment become more diverse every day, in many advanced solid (organ) tumors the desired treatment response is still not achieved. On September 2, 2020, Science Translational Medicine published a study in which researchers sought to overcome this problem by testing the effectiveness of CAR T-cell therapy, which alone is insufficient in solid tumors, together with oncolytic viruses. The results are exciting!
Note: Cancers fall into two main groups: solid (organ) tumors and hematological (originating in blood and bone marrow) cancers. The treatment approaches and drugs used for these two groups differ considerably.
In preclinical trials that offer hope for conducting clinical studies, scientists developed a way to enter solid tumor cells and make them display CD19 protein on their surfaces using an oncolytic virus. After CD19 was displayed on the surface, they used the following to recognize and destroy cancer cells: CD19-targeted CAR T cells.
CD19-targeted CAR T-cell therapy is a treatment approved by the US Food and Drug Administration (FDA) for B-cell lymphoma and acute lymphoblastic leukemia (see related approvals). New research is extremely important for potentially expanding the use of CD19-targeted CAR T cells to treat patients with solid tumors.
The microscope video below shows CD19-CAR T cells attacking virus-infected cancer cells until they are eliminated.
A researcher on the team summarizes the importance of the study as follows: "In treating solid tumors with immunotherapy, we encounter two fundamental problems . The first is inadequate access of T cells to the tumor site. Another problem is that the immunosuppressive environment of solid tumors prevents CAR T cells reaching the tumor from functioning effectively. Our study shows that oncolytic viruses can be used together with CAR T-cell therapy and offers a new treatment method for solid tumors in the future. One of the most important advantages we have provided is that the oncolytic viruses developed help break down the microenvironment barrier formed around the solid tumor that prevents CAR T cells from reaching the area .’
Triple-negative breast cancer, pancreatic cancer, prostate, ovarian, head and neck and brain cancer cell lines and animal models were used in studies in which researchers achieved successful results. In trials using animal models, combining oncolytic viruses with CAR T-cell therapy also showed potent antitumor activity in cancers and produced a long-lasting antitumor immune response.
If the oncolytic viruses, whose safety will be tested in patients, produce positive results, their effectiveness together with CAR T-cell therapy will begin to be tested in clinical studies (human trials). Promising to overcome difficulties encountered in treating solid tumors, this study offers hope to many patients for the future.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.